Aripiprazole
Product Images NDC 17856-0110

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 17856-0110). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (17856 0110 01 Label 1)

Aripiprazole Oral Solution 5 mg/5 mL label with product NDC 17856-0110. The label includes storage instructions to keep at 20° to 25°C (68° to 77°F) and keep out of reach of children. Dosage is indicated as 5 mL per unit, with a quantity of 72 cups per package. Packaged by Unit Dose Solutions in Morrisville, NC, and distributed by Atlantic Biologicals Corp., Miami, FL. Includes reorder phone number 800.509.7592.*

FDA Label Image

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (Aripiprazole Fig1)

A pharmacokinetic chart showing the effects of other drugs on aripiprazole plasma exposure. It displays fold changes with 90% confidence intervals for AUC and Cmax parameters relative to a reference without interacting drugs. The chart includes CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and other drugs like valproate, lithium, and lorazepam, illustrating their impact on aripiprazole levels.*

FDA Label Image

Figure 2: The Effects Of Other Drugs On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig2)

A forest plot chart titled 'The effects of other drugs on dehydro-aripiprazole pharmacokinetics' showing fold changes and 90% confidence intervals for AUC and Cmax of dehydro-aripiprazole with various interacting drugs. Included drugs are ketoconazole (CYP3A4 inhibitor), quinidine (CYP2D6 inhibitor), carbamazepine (CYP3A4 inducer), famotidine (gastric acid blocker), valproate, lithium, and lorazepam. The x-axis represents the fold change relative to reference without an interacting drug, ranging from 0.0 to 3.0.*

FDA Label Image

Figure 3: The Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig3)

A pharmacokinetic effect chart titled 'The effects of aripiprazole on pharmacokinetics of other drugs' showing fold changes with 90% confidence intervals for various drugs and their pharmacokinetic parameters (such as AUC, Cmax, INR) relative to reference values without interacting drug. The chart includes drugs metabolized by CYP2D6, CYP2C9, CYP2C19, UGT1A4, and others like warfarin, omeprazole, lithium, and escitalopram, illustrating their change in exposure when coadministered with aripiprazole.*

FDA Label Image

Figure 4: Effects Of Intrinsic Factors On Aripiprazole Pharmacokinetics (Aripiprazole Fig4)

A graph illustrating the effects of intrinsic factors, including CYP2D6 metabolizer status, gender, age, hepatic impairment, and renal impairment, on the pharmacokinetics of Aripiprazole. The chart shows fold changes and 90% confidence intervals for AUC and Cmax relative to reference populations in special populations.*

FDA Label Image

Figure 5: Effects Of Intrinsic Factors On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig5)

A plot showing the effects of intrinsic factors on dehydro-aripiprazole pharmacokinetics. It presents fold change and 90% confidence intervals for AUC and Cmax relative to reference values, across categories like CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment.*

FDA Label Image

Figure 6: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (schizophrenia Study 5) (Aripiprazole Fig6)

A Kaplan-Meier curve showing the cumulative proportion of patients with relapse over time in days from randomization, comparing Aripiprazole and Placebo in Schizophrenia Study 5. The graph includes the number of subjects at risk at various time points and depicts a lower relapse proportion for Aripiprazole compared to Placebo as time progresses.*

FDA Label Image

Figure 7: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (bipolar Study 7) (Aripiprazole Fig7)

Kaplan-Meier plot showing the cumulative proportion of patients with relapse over time in a bipolar disorder study comparing Aripiprazole and placebo. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion of patients with relapse. The graph includes a risk table indicating the number of subjects at risk at various time points for both Aripiprazole and placebo groups.*

FDA Label Image

Figure 8: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse To Any Mood Event (bipolar Study 8) (Aripiprazole Fig8)

Kaplan-Meier estimation graph showing the cumulative proportion of patients with relapse to any mood event over days from randomization in a bipolar study. The graph compares Aripiprazole and placebo groups, with relapse proportion on the Y-axis and days on the X-axis, including the number of subjects at risk at various time points for each group.*

FDA Label Image

Chemical Structure (Aripiprazole Str)

Chemical structure diagram of Aripiprazole showing the molecular configuration with chlorine atoms, aromatic rings, and functional groups as part of the compound's structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.